Nula Therapeutics Secures $10M Series A From Apollo Health Ventures and $20M ARPA‑H Grant

Why It Matters

Targeting the nuclear envelope could unlock therapies for a spectrum of age‑related and metabolic disorders, positioning Nula at the frontier of precision medicine and longevity research.

Key Takeaways

• Nula raised $30M total, $20M from ARPA‑H, $10M from Apollo
• NLT‑101 will enter Phase 1 for MASH this year, results by 2027
• Funding enables preclinical work on intrinsic capacity in older adults
• Nuclear‑envelope modulation may address metabolic disease, neurodegeneration, cancer

Pulse Analysis

Nula Therapeutics is betting on the nuclear envelope—a cellular structure once thought passive—as a druggable hub for metabolic and age‑related diseases. Recent discoveries show that envelope dysfunction, driven by excess calories or cellular aging, disrupts gene regulation and contributes to conditions like metabolic‑dysfunction‑associated steatohepatitis (MASH). By designing small molecules that restore envelope integrity, Nula hopes to correct the upstream cause rather than merely treating downstream symptoms, a strategy that could reshape therapeutic approaches in hepatology and beyond.

The company’s flagship candidate, NLT‑101, is a proprietary small‑molecule intended to normalize nuclear‑envelope dynamics. Preclinical data in MASH models have been promising enough to secure a Phase 1 trial slated for later this year, with initial safety and pharmacokinetic readouts expected by mid‑2027. Financial backing is robust: ARPA‑H awarded up to $20 million under its PROSPR program to explore NLT‑101’s impact on intrinsic capacity—a composite measure of physical, cognitive, and sensory function—while Apollo Health Ventures contributed $10 million for near‑term development. This dual‑track funding underscores confidence in both the metabolic and geroscience potential of the platform.

If successful, Nula’s approach could have ripple effects across the biotech landscape. Restoring nuclear‑envelope health may influence pathways implicated in neurodegeneration and cancer, expanding the addressable market far beyond liver disease. Moreover, the focus on intrinsic capacity aligns with a growing regulatory and investor appetite for interventions that extend healthspan rather than merely treating isolated ailments. Nula’s progress will be closely watched as a bellwether for whether nuclear‑envelope‑centric therapeutics can deliver on the promise of next‑generation, disease‑modifying medicines.

Deal Summary

New York‑based biotech startup Nula Therapeutics announced it has raised $10 million in a Series A round led by Apollo Health Ventures, alongside a $20 million grant from the U.S. Advanced Research Projects Agency for Health (ARPA‑H) to study aging. The funding will support preclinical work and a Phase 1 trial of its lead candidate NLT‑101 for metabolic disease and age‑related pathologies. The announcement was made on April 16, 2026.